Oxford Science Enterprises, the venture builder backing University of Oxford spinouts, has appointed Dr Jeffrey Moore as new senior partner and head of life sciences.

A scientist by training with a DPhil from Oxford, Dr Moore brings over two decades of BioTech venture capital leadership across North America and Europe.

Dr Moore joins OSE from Boston-based MP Healthcare Venture Management, where he served as president. He has a track record of backing early-stage university spinouts ahead of formal fundraising rounds, including investments in Covagen (acquired by Johnson & Johnson) and Trimtech Therapeutics, which completed a £36m fundraise in June 2026.